ASCENDIS PHARMA A/S - ADR(NASDAQ:ASND) stock News

ASND Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Zacks Investment Research

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade

8 days ago - By: Ascendis Pharma

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

12 days ago - By: Yahoo Finance - Mentions: MS BMRN

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside

15 days ago - By: Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

15 days ago - By: Ascendis Pharma

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

19 days ago - By: Benzinga

Peering Into Ascendis Pharma's Recent Short Interest

a month ago - By: Yahoo Finance

Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook

a month ago - By: Yahoo Finance

BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating

a month ago - By: Yahoo Finance - Mentions: INTU FITB MCK T ...

Mizuho Securities Hikes Intuit Price Target to $875 on Positive QuickBooks Outlook

a month ago - By: Yahoo Finance - Mentions: PNC VZ BMO FI ...

PNC Financial Services Group Unveils PNC Mobile Accept Targeting Micro Business

a month ago - By: Yahoo Finance - Mentions: BMO USB VZ PNC ...

Bank of Montreal (BMO) Strengthens Leadership Group in North America

a month ago - By: Yahoo Finance - Mentions: MS THC EXOD CNC ...

Morgan Stanley Raises Tenet Healthcare (THC) PT to $210, Keeps Overweight Rating

a month ago - By: Yahoo Finance - Mentions: RJF SLB CTRA SLP ...

Coterra Energy price target raised to $38 from $33 at Raymond James

a month ago - By: Yahoo Finance - Mentions: ORCL EXOD SLP CTRA ...

Simulations Plus price target lowered to $36 from $45 at Craig-Hallum

a month ago - By: Yahoo Finance

Ascendis Pharma price target raised to $224 from $215 at Oppenheimer

a month ago - By: Yahoo Finance - Mentions: VZ EFX TM

How to read a credit report

a month ago - By: Yahoo Finance - Mentions: GME ALNY CLF

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

a month ago - By: Yahoo Finance - Mentions: ALNY VRTX GME ALSN ...

The European Commission Approves Alnylam’s AMVUTTRA

a month ago - By: Ascendis Pharma

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

2 months ago - By: Ascendis Pharma

FDA Accepts TransCon® CNP NDA for Priority Review

2 months ago - By: Specialised Therapeutics

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

2 months ago - By: Yahoo Finance - Mentions: UBS CNQ KO ATHA

Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term

2 months ago - By: Ascendis Pharma

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

2 months ago - By: Ascendis Pharma

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

3 months ago - By: Yahoo Finance - Mentions: AZO DHI CMG

Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1

3 months ago - By: Ascendis Pharma

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

3 months ago - By: Ascendis Pharma

Ascendis Pharma Reports First Quarter 2025 Financial Results

3 months ago - By: Ascendis Pharma

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

3 months ago - By: Yahoo Finance - Mentions: MS LMT CAT NET ...

Reddit initiated, Target downgraded: Wall Street's top analyst calls

3 months ago - By: Yahoo Finance - Mentions: ARGX NET NVDA UBER ...

ASCENDIS PHARMA A/S - ADR (ASND) Stock News

ASND Latest News, Press Relases and Analysis

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life

Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025

Peering Into Ascendis Pharma's Recent Short Interest

Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook

BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating

Mizuho Securities Hikes Intuit Price Target to $875 on Positive QuickBooks Outlook

PNC Financial Services Group Unveils PNC Mobile Accept Targeting Micro Business

Bank of Montreal (BMO) Strengthens Leadership Group in North America

Morgan Stanley Raises Tenet Healthcare (THC) PT to $210, Keeps Overweight Rating

Coterra Energy price target raised to $38 from $33 at Raymond James

Simulations Plus price target lowered to $36 from $45 at Craig-Hallum

Ascendis Pharma price target raised to $224 from $215 at Oppenheimer

How to read a credit report

TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26

The European Commission Approves Alnylam’s AMVUTTRA

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

FDA Accepts TransCon® CNP NDA for Priority Review

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

Ascendis Pharma A/S (ASND): Among the Best Growth Stocks to Buy and Hold for the Long Term

New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism

Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1

Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025

Ascendis Pharma Reports First Quarter 2025 Financial Results

Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025

Reddit initiated, Target downgraded: Wall Street's top analyst calls

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?